Magazine article Drug Topics

New Products

Magazine article Drug Topics

New Products

Article excerpt



New drugs

Coria, the newly expanded dermatology division of Valeant, announced the launch of Acanya Qd (clindamycin phosphate 1.2% and benzoyl peroxide 2.5%), indicated for the once-daily treatment of acne vulgaris in patients 12 years and older. Acanya Gel, a fixed combination of antibiotic and benzoyl peroxide (BPO) medication, is approved by the Food and Drug Administration for the once-daily treatment of both noninflammatory and inflammatory acne lesions. The gel was optimized to provide enhanced bioavailability of BPO, creating a product the company says is effective and well tolerated. For more information, visit

MiddleBrook launched Moxatag Tablets 775 mg (extended-release amoxicillin), described as the first and only FDA-approved once-daily amoxicillin treatment. Moxatag is intended to provide a lower-dose, once -daily alternative to currently approved penicillin and amoxicillin regimens for the treatment of adults and pediatric patients 12 years and older with tonsillitis and/or pharyngitis. There is no AB -rated generic for Moxatag. For more information, visit

Fleming launched ProBarlmin QT [1], for patients who have undergone weight-loss surgery and risk developing vitamin and mineral deficiencies because of post-surgery diet restrictions. Formulated with the help of bariatric clinic professionals, ProBarimin QT, a prescription-only vitamin supplement, offers an alternative for safe daily nutritional supplementation. This product quickly dissolves in the mouth without water (helpful for those facing post-surgery liquid-intake restrictions), contains no sugar, and has a pleasant fruit flavor. To leam more, visit

New Indications

Forest announced the FDA approved its New Drug Application (NDA) for Lexapro (escitalopram oxalate) for the acute and maintenance treatment of major depressive disorder (MDD) in adolescents, 12 to 17 years of age. Lexapro is only the second antidepressant to be approved for the treatment of MDD in adolescents, a condition that affects approximately 2 million adolescents in the United States. To leam more, visit

Eli Lilly announced the FDA has approved a new indication for Synv byax (olanzapine and fluoxetine HCl capsules). Symbyax is the first drug approved by the FDA for the acute treatment of treatment-resistant depression (TRD). The new Symbyax TRD indication is for acute treatment of adult patients with MDD who have not responded to two separate trials of different antidepressants of adequate dose and duration in their current episode. …

Search by... Author
Show... All Results Primary Sources Peer-reviewed


An unknown error has occurred. Please click the button below to reload the page. If the problem persists, please try again in a little while.